Lista de obras - Alexandra Leary - Dominio Público Uruguay

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy

artículo científico publicado en 2008

Abnormalities of DNA repair and gynecological cancers

artículo científico publicado en 2017

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

artículo científico publicado en 2014

Adjuvant chemotherapy in stage I ovarian germ cell tumors: should indications and treatment modalities be different in young girls and adults?

artículo científico publicado en 2014

Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants

artículo científico publicado en 2013

An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of

artículo científico publicado en 2007

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.

artículo científico publicado en 2018

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

artículo científico publicado en 2014

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

artículo científico publicado en 2017

Are the outcomes of neoadjuvant chemotherapy for stage IB2 cervical cancer similar in pregnant and nonpregnant patient?

scientific article published on 11 June 2012

Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery

artículo científico publicado en 2018

CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial

scientific article published on 24 March 2020

Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer

artículo científico publicado en 2016

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

artículo científico publicado en 2011

Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type

scientific article published on 01 March 2018

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

artículo científico publicado en 2007

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

artículo científico publicado en 2006

DNA damage response as a therapeutic target in gynecological cancers.

artículo científico publicado en 2016

ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1

artículo científico publicado en 2011

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

scientific article published on 01 April 2019

Endometrial cancer

scientific article published on 06 September 2015

Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors

artículo científico publicado en 2011

Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues

artículo científico publicado en 2016

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours

artículo científico publicado en 2016

Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice

artículo científico publicado en 2015

Histological and molecular classification of endometrial carcinoma and therapeutical implications

artículo científico publicado en 2017

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition

artículo científico publicado en 2016

Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.

artículo científico publicado en 2017

Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy.

artículo científico publicado en 2016

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

artículo científico publicado en 2018

Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials?

scientific article published on 01 March 2006

Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?

artículo científico publicado en 2017

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies

artículo científico publicado en 2016

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

artículo científico publicado en 2006

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative

artículo científico publicado en 2017

Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience

artículo científico publicado en 2018

Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience

artículo científico publicado en 2015

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).

artículo científico publicado en 2016

Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer

scientific article published on 27 August 2020

Novel membrane-based targets - Therapeutic potential in gynecological cancers.

artículo científico publicado en 2014

Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.

artículo científico publicado en 2016

Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment

artículo científico publicado en 2017

Outcome of patients with advanced-stage borderline ovarian tumors after a first peritoneal noninvasive recurrence: impact on further management.

artículo científico publicado en 2015

Ovarian Cancer: A Heterogeneous Disease

artículo científico publicado en 2017

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters

artículo científico publicado en 2015

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

artículo científico publicado en 2016

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

artículo científico publicado en 2018

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

artículo científico publicado en 2015

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.

artículo científico

Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors

scientific article published on 10 September 2018

Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers

artículo científico publicado en 2017

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

artículo científico publicado en 2016

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2017

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

artículo científico publicado en 2015

Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types

artículo científico publicado en 2017

Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases.

artículo científico publicado en 2015

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

artículo científico publicado en 2015

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.

artículo científico publicado en 2017

Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication ⬇️

artículo científico publicado el 16 de junio de 2011

Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.

artículo científico publicado en 2017

Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment

artículo científico publicado en 2013

[Chemotherapy in epithelial ovarian cancer].

artículo científico publicado en 2013

[Erratum to: "Histological and molecular classification of endometrial carcinoma and therapeutical implications" [Bull. Cancer 104 (2017) 1001-1012]].

artículo científico publicado en 2018

[Targeted therapy in locally and metastatic recurrent cervical cancers].

artículo científico publicado en 2014

[The molecular biology of epithelial ovarian cancer]

artículo científico publicado en 2012

Lista de obras de Alexandra Leary

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy

Abnormalities of DNA repair and gynecological cancers

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

Adjuvant chemotherapy in stage I ovarian germ cell tumors: should indications and treatment modalities be different in young girls and adults?

Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants

An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Are the outcomes of neoadjuvant chemotherapy for stage IB2 cervical cancer similar in pregnant and nonpregnant patient?

Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery

CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial

Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

DNA damage response as a therapeutic target in gynecological cancers.

ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Endometrial cancer

Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors

Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours

Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice

Histological and molecular classification of endometrial carcinoma and therapeutical implications

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition

Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.

Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy.

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials?

Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative

Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience

Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).

Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer

Novel membrane-based targets - Therapeutic potential in gynecological cancers.

Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.

Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment

Outcome of patients with advanced-stage borderline ovarian tumors after a first peritoneal noninvasive recurrence: impact on further management.

Ovarian Cancer: A Heterogeneous Disease

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.

Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors

Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types

Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases.

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.

Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication ⬇️

Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.

Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment

[Chemotherapy in epithelial ovarian cancer].

[Erratum to: "Histological and molecular classification of endometrial carcinoma and therapeutical implications" [Bull. Cancer 104 (2017) 1001-1012]].

[Targeted therapy in locally and metastatic recurrent cervical cancers].

[The molecular biology of epithelial ovarian cancer]